Structure via PubChem · Public domain (PubChem)
iniparib
Sign in to saveAlso known as BSI-201, SAR240550, 4-iodo-3-nitrobenzamide
Iniparib (INN, previously known as BSI 201) was a drug candidate for cancer treatment. It was originally believed to act as an irreversible inhibitor of PARP1 (hence, a PARP inhibitor) and possibly other enzymes through covalent modification, but its effects against PARP were later disproven. It underwent clinical trials for treatment of some types of breast cancer, but was discontinued after disappointing phase III clinical trials.
Chemical data
- Formula
- C7H5IN2O3
- Molecular weight
- 292.03 g/mol
- IUPAC name
- 4-iodo-3-nitrobenzamide
- SMILES
- C1=CC(=C(C=C1C(=O)N)[N+](=O)[O-])I
- InChIKey
- MDOJTZQKHMAPBK-UHFFFAOYSA-N
- XLogP
- 1.3
- Polar surface area
- 88.9 Ų
- H-bond donors
- 1
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- neoplasm, squamous cell lung carcinoma, non-small cell lung carcinoma, Uterine Carcinosarcoma
via ChEMBL · EBI
Research
100 papers- Appraising iniparib, the PARP inhibitor that never was--what must we learn?Nature reviews. Clinical oncology · 2013
- Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer.IDrugs : the investigational drugs journal · 2010
- Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics.Breast cancer research and treatment · 2019
- Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019
- Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer.The oncologist · 2023
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 291.934
- Has use
- medication
Show 3 more facts
- chemical formula
- C₇H₅IN₂O₃
- canonical SMILES
- C1=CC(=C(C=C1C(=O)N)[N+](=O)[O-])I
- subject has role
- PARP inhibitor
Sources (2)
via Wikidata · CC0
~2 min read
Encyclopedic overview
2 sectionsContents
- History
- References
Iniparib (INN, previously known as BSI 201) was a drug candidate for cancer treatment. It was originally believed to act as an irreversible inhibitor of PARP1 (hence, a PARP inhibitor) and possibly other enzymes through covalent modification, but its effects against PARP were later disproven. It underwent clinical trials for treatment of some types of breast cancer, but was discontinued after disappointing phase III clinical trials.
==History== Iniparib was the first putative PARP inhibitor to commence phase III clinical trials. The first was for breast cancer, another was for squamous-cell lung cancer. Preliminary results in June 2009 on triple-negative breast cancer were promising. Later results showed increased median survival of triple-negative breast cancer patients from 7.7 to 12.2 months.
Excerpted from Wikipedia’s “iniparib” article, available under the CC BY-SA 4.0 licence.